Food and Drug Administration (FDA) will hold public hearings on CBD in April, according to statements made by FDA Commissioner Scott Gottlieb, during a recent House Appropriations subcommittee hearing. The purpose of the public hearing will be to start the rule-making process and gather stakeholder input on how the FDA can regulate hemp-derived CBD.
In addition, FDA will form a working group of senior officials and agency experts to advise the Commissioner on regulatory options. Gottlieb affirmed Congress wants a path for regulating food and dietary supplements containing CBD. Gottlieb said, “this is not a straightforward process. There’s not a good proxy for us doing this through regulation.”
The conceptual regulatory framework includes a pharmaceutical path and a path for food products and dietary supplements. Gottlieb specifically mentions FDA approved CBD epilepsy medication, Epidiolex and wanting to maintain a motivation to study CBD for pharmaceutical products by keeping a pharmaceutical regulatory framework.
Although Gottlieb declared his attention to the complexities of regulating CBD, he recently announced his April resignation for personal reasons, almost a year after his appointment as FDA Commissioner.
McAllister Garfield, P.C. is busy advising hemp and CBD companies during this time of transition. For more information, contact attorney David Wunderlich at firstname.lastname@example.org.